<p>EQL Pharma</p>
<p>EQL Pharma 在第二季度經歷了來自多個供應商的交付延遲，導致該季度銷售損失。交付將會到來，但失去的銷售無法在第三和第四季度彌補。預計 2025/26 財年的全年業績增長將更接近 15% 而非 30%。</p>
<p>交付延遲還導致原定於第二季度進行的產品發佈推遲。這些發佈將改為在第三季度末或第四季度初進行。</p>
<p>由於交付延遲，EQL Pharma 宣佈第二季度的銷售預計將略低於 90（85.2）百萬瑞典克朗，即與去年同期相比實現單數字增長。</p>
<p>利潤也受到影響，但影響程度不如銷售顯著。預計 2025/26 財年的 EBITDA 利潤率將更接近 20% 而非 25%。</p>
<p>這些問題是暫時性的，不會影響公司最近公佈的五年目標的實現前景。</p>
<p>所有數據均為初步數據，未經審計。EQL Pharma 第二季度的完整業績將於 2025 年 11 月 5 日（星期三）公佈。</p>
<p>本披露包含 EQL Pharma 根據歐盟市場濫用法規（EU nr 596/2014）和瑞典證券市場法（2007:528）有義務公開的信息。該信息於 2025 年 9 月 22 日 22:35 CET 通過聯繫人提交發布。</p>
<p>如需更多信息，請聯繫：</p>
<p>Axel Schörling，</p>
<p>EQL Pharma AB（公眾）首席執行官兼總裁</p>
<p>電話：+46 (0) 76 317 90 60</p>
<p>電子郵件：axel.schorling@eqlpharma.com</p>
<p>網站：www.eqlpharma.com</p>
<p>EQL Pharma AB（公眾）簡介</p>
<p>EQL Pharma AB 專注於開發和銷售仿製藥，即在醫學上等同於原研藥的藥物。該公司目前在北歐市場推出了 46 種小眾仿製藥（即與原研藥競爭有限的仿製藥）。除了這些產品外，還有大量小眾仿製藥的管道計劃於 2025 年及以後推出。該業務目前完全專注於處方藥，包括醫院產品，主要在北歐和歐洲市場。EQL Pharma AB 在隆德運營，並在納斯達克斯德哥爾摩證券市場上市。EQL Pharma AB 與歐盟和亞洲等地的領先合同製造商和大型製藥公司開展廣泛的開發合作。</p>
<p>https://news.cision.com/eql-pharma/r/delivery-delays-mean-that-the-second-quarter-and-thus-the-full-year-2025-26-will-be-weaker-than-expe%2Cc4238282</p>
<p>新聞稿 2025-09-22 盈利警告</p>

平等行業權重 ETF - ALPS

<p>EQL Pharma 報告稱，第二季度供應商交貨延遲導致銷售損失，並對 2025/26 財年的前景產生了負面影響，預計增長將接近 15%，而非 30%。第二季度的銷售預計將略低於 90 百萬瑞典克朗，反映出同比的個位數增長。預計 EBITDA 利潤率將約為 20%。原定於第二季度的產品發佈已推遲至第三季度末或第四季度初。公司保證這些問題是暫時的，不會影響其五年目標。完整的財務結果將於 2025 年 11 月 5 日披露</p>

<p>EQL Pharma</p>
<div class="lb-trans"><p>EQL Pharma</p>
</div><p>EQL Pharma has experienced delays in deliveries from several suppliers during the second quarter, resulting in lost sales during the quarter. Deliveries will come, but the lost sales cannot be made up for in the third and fourth quarters. Full-year results for the 2025/26 financial year are expected to be closer to 15 than 30 percent growth.</p>
<div class="lb-trans"><p>EQL Pharma 在第二季度經歷了來自多個供應商的交付延遲，導致該季度銷售損失。交付將會到來，但失去的銷售無法在第三和第四季度彌補。預計 2025/26 財年的全年業績增長將更接近 15% 而非 30%。</p>
</div><p>The delivery delays have also led to postponements of launches that were supposed to take place in Q2. These will instead take place towards the end of Q3 or early in Q4.</p>
<div class="lb-trans"><p>交付延遲還導致原定於第二季度進行的產品發佈推遲。這些發佈將改為在第三季度末或第四季度初進行。</p>
</div><p>As a result of the delivery delays, EQL Pharma announces that sales in the second quarter are expected to land just under 90 (85.2) MSEK, i.e. a single-digit growth compared to the same quarter last year.</p>
<div class="lb-trans"><p>由於交付延遲，EQL Pharma 宣佈第二季度的銷售預計將略低於 90（85.2）百萬瑞典克朗，即與去年同期相比實現單數字增長。</p>
</div><p>Profit is also affected, but not as significantly as sales. Here, an EBITDA margin closer to 20 than 25 percent is expected for the full year 2025/26.</p>
<div class="lb-trans"><p>利潤也受到影響，但影響程度不如銷售顯著。預計 2025/26 財年的 EBITDA 利潤率將更接近 20% 而非 25%。</p>
</div><p>The problems are of a temporary nature and do not affect the prospects of delivering on the Company's recently communicated five-year target.</p>
<div class="lb-trans"><p>這些問題是暫時性的，不會影響公司最近公佈的五年目標的實現前景。</p>
</div><p>All figures are preliminary and unaudited. EQL Pharma's results for the second quarter will be presented in full on Wednesday, November 5, 2025.</p>
<div class="lb-trans"><p>所有數據均為初步數據，未經審計。EQL Pharma 第二季度的完整業績將於 2025 年 11 月 5 日（星期三）公佈。</p>
</div><p>This disclosure contains information that EQL Pharma is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 22-09-2025 22:35 CET.</p>
<div class="lb-trans"><p>本披露包含 EQL Pharma 根據歐盟市場濫用法規（EU nr 596/2014）和瑞典證券市場法（2007:528）有義務公開的信息。該信息於 2025 年 9 月 22 日 22:35 CET 通過聯繫人提交發布。</p>
</div><p>For more information contact:</p>
<div class="lb-trans"><p>如需更多信息，請聯繫：</p>
</div><p>Axel Schörling,</p>
<div class="lb-trans"><p>Axel Schörling，</p>
</div><p>CEO &amp; President EQL Pharma AB (publ)</p>
<div class="lb-trans"><p>EQL Pharma AB（公眾）首席執行官兼總裁</p>
</div><p>Phone: +46 (0) 76 317 90 60</p>
<div class="lb-trans"><p>電話：+46 (0) 76 317 90 60</p>
</div><p>E-mail: axel.schorling@eqlpharma.com</p>
<div class="lb-trans"><p>電子郵件：axel.schorling@eqlpharma.com</p>
</div><p>Web: www.eqlpharma.com</p>
<div class="lb-trans"><p>網站：www.eqlpharma.com</p>
</div><p>EQL Pharma AB (publ) in short</p>
<div class="lb-trans"><p>EQL Pharma AB（公眾）簡介</p>
</div><p>EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has 46 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2025 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, mainly in the Nordics and European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm stock market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.</p>
<div class="lb-trans"><p>EQL Pharma AB 專注於開發和銷售仿製藥，即在醫學上等同於原研藥的藥物。該公司目前在北歐市場推出了 46 種小眾仿製藥（即與原研藥競爭有限的仿製藥）。除了這些產品外，還有大量小眾仿製藥的管道計劃於 2025 年及以後推出。該業務目前完全專注於處方藥，包括醫院產品，主要在北歐和歐洲市場。EQL Pharma AB 在隆德運營，並在納斯達克斯德哥爾摩證券市場上市。EQL Pharma AB 與歐盟和亞洲等地的領先合同製造商和大型製藥公司開展廣泛的開發合作。</p>
</div><p>https://news.cision.com/eql-pharma/r/delivery-delays-mean-that-the-second-quarter-and-thus-the-full-year-2025-26-will-be-weaker-than-expe%2Cc4238282</p>
<div class="lb-trans"><p>https://news.cision.com/eql-pharma/r/delivery-delays-mean-that-the-second-quarter-and-thus-the-full-year-2025-26-will-be-weaker-than-expe%2Cc4238282</p>
</div><p>Press Release 2025-09-22 Profit warning</p>
<div class="lb-trans"><p>新聞稿 2025-09-22 盈利警告</p>
</div>

交付延遲意味着 2025/26 財年的第二季度以及全年表現將低於預期